Circulating free fatty acids are increased independently of PPARγ activity after administration of poloxamer 407 to mice

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 9, 2008, Pages 643-649

  Johnston, Thomas P ^a   Waxman, David J ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b Boston University   (United States)

Author keywords

Free fatty acid; Glucose; Insulin; Peroxisome proliferator activated receptor (PPAR); Transactivation assay

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; FATTY ACID; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLOXAMER; SURFACTANT; TROGLITAZONE;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; C57BL 6 MOUSE; CHOLESTEROL TRANSPORT; CONCENTRATION RESPONSE; DYSLIPIDEMIA; FATTY ACID TRANSPORT; GENETIC TRANSCRIPTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; MACROPHAGE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSACTIVATION;

ANIMALS; BLOOD GLUCOSE; CHROMANS; FATTY ACIDS, NONESTERIFIED; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLASMIDS; POLOXAMER; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS);

EID: 50849130253     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-070     Document Type: Article

References (34)

1. Auwerx, J. 1999. PPARγ, the ultimate thrifty gene. Diabetologia, 42: 1033-1049. doi:10.1007/s001250051268. PMID:10447513.
2. Bays, H., Mandarino, L., and DeFronzo, R.A. 2004. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin. Endocrinol. Metab. 89: 463-478. doi:10.1210/jc.2003-030723. PMID:14764748.
3. Berger, J.P., Akiyama, T.E., and Meinke, P.T. 2005. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26: 244-250. doi:10.1016/j.tips.2005.03.003. PMID:15860371.
4. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. 1996. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology, 137: 354-366. doi:10.1210/en.137.1.354. PMID:8536636.
5. Chang, T.K., and Waxman, D.J. 2005. Pregnane X receptor-mediated transcription. Methods Enzymol. 400: 588-598. doi:10.1016/S0076-6879(05) 00033-9. PMID:16399372.
6. Chawla, A., Schwarz, E.J., Dimaculangan, D.D., and Lazar, M.A. 1994. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 135: 798-800. doi:10.1210/en.135.2.798. PMID:8033830.
7. Chawla, A., Boisvert, W.A., Lee, C.H., Laffitte, B.A., Barak, Y., Joseph, S.B., et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell, 7: 161-171. doi:10.1016/S1097-2765(01)00164-2. PMID:11172721.
8. Chinetti, G., Fruchart, J.C., and Staels, B. 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49: 497-505. doi:10.1007/s000110050622. PMID:11089900.
9. Chinetti, G., Lestavel, S., Bocher, V., Remaley, A.T., Neve, B., Pineda, T.I., et al. 2001. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58. doi:10.1038/83348. PMID:11135616.
10. Gonzalez, F.J. 1997. Recent update on the PPAR α-null mouse. Biochimie, 79: 139-144. doi:10.1016/S0300-9084(97)81506-4. PMID:9209711.
11. He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., et al. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver, but not in muscle. Proc. Natl. Acad. Sci. U.S.A. 100: 15712-15717. doi:10.1073/pnas.2536828100. PMID:14660788.
12. Johnston, T.P. 2004. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J. Cardiovasc. Pharmacol. 43: 595-606. doi:10.1097/00005344-200404000-00016. PMID:15085072.
13. Johnston, T.P., and Palmer, W.K. 1997. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29: 580-585. doi:10.1097/00005344-199705000-00003. PMID:9213198.
14. Johnston, T.P., and Waxman, D.J. 2008. The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα. J. Pharm. Pharmacol. 60: 753-759. doi:10.1211/jpp.60.6.0011. PMID:18498712.
15. Johnston, T.P., Emeson, E.E., and Palmer, W.K. 1998. Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis, 136: 115-123. doi:10.1016/S0021-9150(97)00193-7. PMID:9544738.
16. Johnston, T.P., Jaye, M., Webb, C.L., Krawiec, J.A., Alom-Ruiz, S.P., Sachs-Barrable, K., et al. 2006. Poloxamer 407 (P-407)-mediated reduction in the gene expression of ATP-bindingcassette transporter A1 may contribute to increased cholesterol in peripheral tissues of P-407-treated rats. Eur. J. Pharmacol. 536: 232-240. doi:10.1016/j.ejphar.2006.03.019. PMID:16603153.
17. Kersten, S., Desvergne, B., and Wahli, W. 2000. Roles of PPARs in health and disease. Nature, 405: 421-424. doi:10.1038/35013000. PMID:10839530.
18. Kliewer, S.A., Forman, B.M., Blumberg, B., Ong, E.S., Borgmeyer, U., Mangelsdorf, D.J., et al. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A. 91: 7355-7359. doi:10.1073/pnas.91.15.7355. PMID:8041794.
19. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Wilson, T.M., and Kliewer, S.A. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270: 12953-12956. doi:10.1074/jbc.270.50. 30221. PMID:7768881.
20. Leon, C., Wasan, K.M., Sachs-Barrable, K., and Johnston, T.P. 2006. Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharm. Res. 23: 1597-1607. doi:10.1007/s11095-006-0276-8. PMID:16783477.
21. Maloney, E.K., and Waxman, D.J. 1999. trans-activation of PPARα and PPARγ by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 161: 209-218. doi:10.1006/taap.1999.8809. PMID:10581215.
22. Mukherjee, R., Davies, P.J., Crombie, D.L., Bischoff, E.D., Cesario, R.M., Jow, L., et al. 1997. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 386: 407-410. doi:10.1038/386407a0. PMID:9121558.
23. Nash, V.J., Johnston, T.P., and Palmer, W.K. 1996. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy, 16: 10-15. PMID:8700787.
24. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., et al. 1998. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101: 1354-1361. doi:10.1172/JCI1235. PMID:9502777.
25. Palmer, W.K., Emeson, E.E., and Johnston, T.P. 1997. The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med. Sci. Sports Exerc. 29: 1416-1421. PMID:9372476.
26. Peters, J.M., Zhou, Y.C., Ram, P.A., Lee, S.S., Gonzalez, F.J., and Waxman, D.J. 1996. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol. Pharmacol. 50: 67-74. PMID:8700121.
27. Pineda, T.I., Gervois, P., and Staels, B. 1999. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis, and aging. Curr. Opin. Lipidol. 10: 151-159. doi:10.1097/00041433-199904000-00009. PMID:10327283.
28. Rangwala, S.M., and Lazar, M.A. 2004. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol. Sci. 25: 331-336. doi:10.1016/j.tips.2004.03.012. PMID:15165749.
29. Saltiel, A.R., and Olefsky, J.M. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 45: 1661-1669. doi:10.2337/diabetes.45.12.1661. PMID:8922349.
30. Shipley, J.M., and Waxman, D.J. 2004. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol. Appl. Pharmacol. 199: 275-284. doi:10.1016/j.taap.2003.12.020. PMID:15364543.
31. Shipley, J.M., Hurst, C.H., Tanaka, S.S., DeRoos, F.L., Butenhoff, J.L., Seacat, A.M., et al. 2004. trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals. Toxicol. Sci. 80: 151-160. doi:10.1093/toxsci/kfh130. PMID:15071170.
32. Spiegelman, B.M., and Flier, J.S. 1996. Adipogenesis and obesity: Rounding out the big picture. Cell, 87: 377-389. doi:10.1016/S0092- 8674(00)81359-8. PMID:8898192.
33. Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I., and Spiegelman, B.M. 1994. mPPARγ 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8: 1224-1234. doi:10.1101/gad.8.10.1224. PMID:7926726.
34. Wasan, K.M., Subramanian, R., Kwong, M., Goldberg, I.J., Wright, T., and Johnston, T.P. 2003. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J. Pharm. Pharm. Sci. 6: 189-197.